PT-141 (Bremelanotide) Explained: How It Works for Women and Men
PT-141, also called bremelanotide, works on desire pathways in the brain rather than blood flow. Learn what is FDA-approved, what is off-label for men, what studies show and the key safety points.
PT-141 is the research name for bremelanotide, a peptide that activates melanocortin receptors in the brain involved in sexual desire and arousal. Brand bremelanotide (Vyleesi) is FDA-approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Use in men, and all compounded PT-141, is off-label and not FDA-approved, and a licensed provider decides whether it is appropriate for you.
Key takeaways
- PT-141 works in the brain on desire pathways, unlike tadalafil and sildenafil, which work on blood flow.
- Vyleesi was approved in 2019 for premenopausal women with low sexual desire that causes distress and is not explained by another condition, a relationship problem or a medication.
- The label states it is not indicated for postmenopausal women, for men, or to enhance sexual performance.
- Early trials in men tested PT-141 for erectile dysfunction, but it has not been approved for men.
- The most common side effect is nausea. Blood pressure rises temporarily after each dose, so it is not for people with uncontrolled high blood pressure or known heart disease.
How PT-141 works
Melanocortins are signaling molecules that help regulate appetite, skin pigment and sexual function. PT-141 activates melanocortin receptors, particularly in brain areas linked with sexual motivation. The FDA label notes that the exact way it improves desire is not known.
That brain-based action is the key difference from ED medications. Tadalafil and sildenafil improve blood flow once arousal is present. PT-141 aims at the desire and arousal side of the equation. For some people, that difference is exactly why it is worth discussing.
What is FDA-approved and what is off-label
| Use | Status |
|---|---|
| Brand Vyleesi for premenopausal women with acquired, generalized HSDD | FDA-approved (2019) |
| Bremelanotide for postmenopausal women | Off-label, not FDA-approved for this use |
| Bremelanotide for men | Off-label, not FDA-approved for this use |
| Compounded PT-141 for anyone | Not FDA-approved |
The RULE PT-141 program uses compounded bremelanotide, prepared by a licensed US pharmacy, for women or men when a licensed provider decides it is appropriate. Compounded medications are not FDA-approved, and off-label use means the provider is relying on clinical judgment and the available evidence rather than an approved indication.
What studies show in women
The approval of Vyleesi was based on two identical phase 3 trials called RECONNECT. About 1,250 premenopausal women with HSDD were randomly assigned to bremelanotide or placebo for 24 weeks, using it as needed before sexual activity.
Women using bremelanotide reported statistically significant improvements in sexual desire and reductions in distress about low desire compared with placebo. The changes were modest on average, and the FDA noted there was no difference between groups in the number of satisfying sexual events. Nausea, flushing and headache were more common with bremelanotide.
In short, PT-141 can help some women with a specific, diagnosed form of low desire. It is not a performance enhancer, and results vary.
What studies show in men
PT-141 was first developed with men in mind. In a 2004 placebo-controlled study, an intranasal form produced a measurable erectile response in healthy men and in men with mild to moderate ED. Later research moved to the injectable form and to women, and bremelanotide was never approved for men.
Some providers prescribe PT-141 off-label for men with low desire, or for men who do not respond well to PDE5 inhibitors. The evidence for men is limited to early-stage studies, so your provider weighs it carefully against your history.
Safety points from the label
Blood pressure and heart rate. Blood pressure rises and heart rate falls slightly after each dose, usually returning to baseline within 12 hours. Bremelanotide is not used in people with uncontrolled high blood pressure or known cardiovascular disease, and it is not recommended for people at high risk of heart disease.
Nausea. About 40% of women in the trials had nausea, most often after the first dose, and it improved for most people with later doses. Some needed anti-nausea medication.
Skin darkening. About 1% of trial participants developed darkened patches of skin, including on the face, gums and breasts. It was more likely with darker skin and with more frequent use, and it did not always resolve after stopping.
Medication interactions. Bremelanotide slows stomach emptying and can lower the levels of some oral medications. MedlinePlus advises telling your prescriber if you take oral naltrexone, indomethacin or oral antibiotics.
Other common effects. Flushing, headache, vomiting, nasal stuffiness and injection-site reactions.
Pregnancy. Tell your provider if you are pregnant, planning a pregnancy or breastfeeding. Use effective birth control during treatment.
Your provider sets the dose and how often you may use it.
PT-141 compared with ED medications
| PT-141 | Tadalafil or sildenafil | |
|---|---|---|
| Main target | Desire and arousal pathways in the brain | Blood flow to the penis |
| Form | Injection under the skin | Tablet |
| FDA approval | Vyleesi for premenopausal women with HSDD only | FDA-approved for erectile dysfunction in men |
| Common side effects | Nausea, flushing, headache | Headache, flushing, indigestion, nasal congestion |
Some men ask about combining PT-141 with a PDE5 inhibitor. That decision belongs to your provider, who will review your blood pressure and heart health first.
Frequently asked questions
Does PT-141 work for men?
Early studies in men showed an erectile response, but PT-141 has not been approved for men, and the evidence is limited. A licensed provider may consider it off-label after reviewing your history and blood pressure.
Is PT-141 the same as Vyleesi?
They share the same active ingredient, bremelanotide. Vyleesi is the FDA-approved brand made under FDA oversight. Compounded PT-141 is prepared by a pharmacy and is not FDA-approved.
How quickly does PT-141 work?
The Vyleesi label describes use at least 45 minutes before anticipated sexual activity. The duration of effect varies by person. Your provider explains timing for your prescription.
Can I use PT-141 if I have high blood pressure?
Not if it is uncontrolled. Because bremelanotide temporarily raises blood pressure, the label says it should not be used with uncontrolled hypertension or known heart disease. Share your readings with your provider.
Talk to a licensed provider
If low desire or arousal is affecting your life or your relationship, start a secure online visit. A licensed provider will review your health history, discuss whether PT-141 or another option fits, and decide whether a prescription is appropriate for you.
Sources
- FDA label via DailyMed, Vyleesi (bremelanotide injection) prescribing information
- FDA label, Vyleesi (bremelanotide injection) original 2019 prescribing information
- Kingsberg SA et al., Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials, Obstet Gynecol 2019 (PubMed)
- Diamond LE et al., Double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction, Int J Impot Res 2004 (PubMed)
- MedlinePlus, Bremelanotide Injection
Reviewed October 28, 2026.
This article is educational and is not medical advice. Rx programs require an online visit with a licensed provider. Results vary.